FDA Refuses Imports from Indian API Maker

Oct 21, 2015

RAPS

The U.S. FDA banned Indian active pharmaceutical ingredient (API) manufacturer Megafine Pharma's Nashik site in Maharashtra, India, from sending products to the United States, according to RAPS.

Megafine, which was hit with an FDA Form 483 back in May at the site, produces 24 APIs for the U.S. market (as well as the EU market), including for drugs treating Alzheimer's, depression, schizophrenia, multiple sclerosis and overactive bladders, the article said.

Read the full story

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments